查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529888

急性骨髓性白血病治療市場規模、佔有率和趨勢分析報告：按疾病、治療方法、給藥途徑、最終用途、地區和細分市場進行預測，2024-2030年

Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report By Disease (Myeloblastic Leukemia, Myelomonocytic Leukemia), By Treatment (Chemotherapy), By Route Of Administration, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 175 Pages | 商品交期: 2-10個工作天內

價格

市場規模及趨勢

預計2023年全球急性骨髓性白血病治療市場規模為31.8億美元，預計2024年至2030年複合年成長率為10.44%。對先進療法的需求不斷成長也是推動該市場的一個主要因素。急性骨髓性白血病藥物發生率增加是由於基因突變、不健康的生活方式、持續接觸苯等有害化學物質以及輻射等因素造成的。此外，老年人口的增加和未滿足的醫療保健需求的增加預計將進一步推動市場成長。美國癌症協會估計，到 2024 年，大約有 20,800 人將被診斷出患有急性骨髓性白血病。

急性骨髓性白血病（AML）治療市場由與治療藥物和治療相關的幾個關鍵因素所驅動。關鍵促進因素之一是新治療方法的持續進步和核准。例如，2023年7月，FDA核准quizartinib（Vanflyta）合併標準化療用於治療新診斷的FLT3-ITD陽性AML成年患者。這項核准凸顯了針對 AML 特定基因突變、改善患者預後和擴大治療選擇的標靶治療的重要性。這些進步不僅提高了治療方法的有效性，也為傳統治療方法選擇有限的患者帶來了新的希望。

另一個主要推動因素是製藥公司對研發的大量投資。例如，2023 年 12 月授予的 600 萬美元津貼用於開發高風險 AML 患者的新治療方法，體現了 Masu 對這一領域創新的堅定承諾。這些投資對於發現新治療方法和改進現有治療方法至關重要，從而推動市場成長。此外，製藥公司、研究機構和學術中心之間的合作和夥伴關係對於加速新的 AML治療方法的開拓發展、進一步推動市場擴張至關重要。

儘管取得了這些進展，但 AML 治療市場仍面臨一些限制因素。主要挑戰之一是新治療方法的高成本。創新治療方法的開發、核准和商業化通常非常昂貴，導致患者和醫療保健系統的成本高昂。這種財務負擔可能會限制獲得尖端治療的機會，特別是在低收入和中等收入國家，並阻礙整體市場成長。

另一個主要阻礙因素是與 AML 治療相關的副作用。化療仍然是 AML 治療的主要手段，但它可能會導致嚴重的副作用，例如疲勞、噁心和感染疾病風險增加。這些副作用對患者的生活品質有重大影響，有時會導致治療停止。即使是新的標靶治療，儘管精度很高，但也會對患者的耐受性構成挑戰。例如，維奈托克與其他治療方法的組合雖然很有前景，但已顯示出必須謹慎管理的副作用。

此外，嚴格的法規環境也是一項挑戰。新藥的核准過程非常嚴格，需要廣泛的臨床試驗以確保安全性和有效性。雖然這些法規對於病人安全至關重要，但它們可能會減緩新藥推向市場的速度。這些冗長的核准流程可能會對及時獲得創新治療造成障礙，並影響快速回應新治療需求的能力。

全球急性骨髓性白血病治療市場報告細分

該報告預測了2018年至2030年全球、區域和國家層面的收益成長，並對每個子區隔的最新行業趨勢進行了分析。在這項研究中，Grand View Research 根據疾病、治療、給藥途徑、最終用途和地區對全球急性骨髓性白血病治療市場報告進行了細分。

  • 按疾病分類的展望（銷售額，2018-2030）
  • 粒細胞白血病
  • 粒單核細胞白血病。
  • 早幼粒細胞白血病。
  • 單核細胞白血病。
  • 其他疾病。
  • 治療展望（銷售，2018-2030）
  • 化療。

抗代謝藥

烷化劑

細胞週期蛋白

其他

  • 標靶治療

FLT3抑制劑

還原

萬弗利普塔

佐斯帕塔

IDH抑制劑

奇夫索沃

萊斯利迪亞

伊迪法

米洛塔格

BCL-2抑制劑

本克雷斯塔

Hedgehog途徑抑制劑

達烏裡主義

  • 免疫療法

雙特異性抗體

抗體-藥物偶聯物

免疫查核點抑制劑

嵌合體抗原受體 (CAR) T 細胞療法

  • 其他治療
  • 管理途徑展望（銷售，2018-2030）
  • 注射劑
  • 口服
  • 最終用途展望（收入，2018-2030）
  • 醫院和診所
  • 專業中心
  • 居家照護設置
  • 門診護理中心
  • 地區展望（銷售額，2018-2030）
  • 北美洲

美國。

加拿大

墨西哥

  • 歐洲

德國

英國

法國

義大利

西班牙

丹麥

瑞典

挪威

  • 亞太地區

中國

日本

印度

韓國

澳洲

泰國

  • 拉丁美洲

巴西

阿根廷

  • 中東和非洲 (MEA)

南非

沙烏地阿拉伯

阿拉伯聯合大公國

科威特

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章急性骨髓性白血病治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 急性骨髓性白血病治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析

第4章急性骨髓性白血病治療市場：疾病估計與趨勢分析

  • 急性骨髓性白血病治療的全球市場：疾病儀表板
  • 全球急性骨髓性白血病治療市場：疾病波動分析
  • 急性骨髓性白血病治療的全球市場（按疾病和收益）
  • 粒細胞白血病
  • 粒單核細胞白血病
  • 早幼粒細胞白血病
  • 單核細胞白血病
  • 其他疾病

第5章急性骨髓性白血病治療市場：治療評估與趨勢分析

  • 急性骨髓性白血病治療的全球市場：治療儀表板
  • 急性骨髓性白血病治療的全球市場：治療變異分析
  • 按治療分類的收益
  • 化療
  • 標靶治療

5.5.2.1.1。

5.5.2.1.1.1. 2018-2030 年 Rydapt 市場估計與預測

5.5.2.1.2。

5.5.2.1.2.1. 2018-2030 年 Vanfrita 市場估計與預測

5.5.2.1.3.索斯帕塔

5.5.2.1.3.1. 2018-2030 年 Xospata 市場估計與預測

  • IDH抑制劑

5.5.3.1.1.蒂布索沃

5.5.3.1.1.1.2018-2030 年 Tibsovo 市場估計與預測

5.5.3.1.2.萊斯利迪亞

5.5.3.1.2.1. 2018-2030 年 Rezlidhia 市場估計與預測

5.5.3.1.3.伊迪法

5.5.3.1.3.1. 2018 年至 2030 年伊迪法市場估計與預測

  • 米洛塔格
  • BCL-2抑制劑

5.5.5.1.1。

5.5.5.1.1.1. 2018 年至 2030 年 Venclexta 市場估計與預測

  • Hedgehog途徑抑制劑

5.5.6.1.1.道主義

5.5.6.1.1.1. 2018 年至 2030 年 Daurismo 市場估計與預測

  • 免疫療法
    • 2018-2030年免疫治療市場估計與預測

5.6.1.1.1. 2018-2030 年雙特異性抗體市場估計與預測

5.6.1.4.1. 2018-2030 年免疫查核點抑制劑市場估計與預測

5.6.1.5.1. 2018 年至 2030 年嵌合嵌合體受體 (CAR) T 細胞治療市場估計與預測

  • 其他治療方法
    • 2018-2030 年其他治療市場估計與預測

第6章急性骨髓性白血病治療市場：給藥途徑估算及趨勢分析

  • 急性骨髓性白血病治療的全球市場：給藥途徑儀表板
  • 全球急性骨髓性白血病治療市場：給藥途徑的變異分析
  • 途徑的收益
  • 胃腸外的
  • 口服

第7章急性骨髓性白血病治療市場：最終用途估計與趨勢分析

  • 急性骨髓性白血病治療的全球市場：最終用途儀表板
  • 全球急性骨髓性白血病治療市場：最終用途變化分析
  • 按最終用途分類的收益
  • 醫院和診所
  • 專業中心
  • 居家照護環境

第 8 章急性骨髓性白血病治療市場：按治療、治療層級和給藥途徑進行的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第9章 競爭格局

  • 公司/競爭對手分類
  • 供應商情況
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Astellas Pharma Inc.
    • Bristol Myers Squibb Company
    • Celgene Corporation
    • Daiichi Sankyo Company, Limited
    • Jazz Pharmaceuticals, plc
    • Novartis AG
    • Otsuka Pharmaceuticals Co., Ltd.
    • Pfizer, Inc.
    • Rigel Pharmaceuticals, Inc.
    • Merck &Co., Inc.
    • Sanofi
Product Code: GVR-4-68040-384-0

Market Size & Trends

The global acute myeloid leukemia treatment market size was estimated at USD 3.18 billion in 2023 and is expected to grow at a CAGR of 10.44% from 2024 to 2030. The increasing need for advanced therapeutics is also a high-impact rendering driver of this market. Rising incidences of acute myeloid leukemia therapeutics are attributed to factors such as genetic mutations, unhealthy lifestyles, continued exposure to hazardous chemicals such as benzene, and radiation exposure. Moreover, the increasing geriatric population base and growing unmet healthcare needs are expected to boost the market growth further. According to the estimates given by American Cancer Society in 2024, around 20,800 people were diagnosed with Acute Myeloid Leukemia.

The market for Acute Myeloid Leukemia (AML) treatment is driven by several key factors related to therapeutics and treatments. One significant driver is the continuous advancement and approval of novel therapies. For instance, in July 2023, the FDA approved quizartinib (Vanflyta) in combination with standard chemotherapies for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML. This approval highlights the importance of targeted therapies that address specific genetic mutations in AML, improving patient outcomes and expanding treatment options. Such advancements not only enhance the efficacy of treatment regimens but also provide new hope for patients with limited options under conventional therapies.

Another major driver is the significant investment in research and development by pharmaceutical companies. For instance, a USD 6 million grant awarded in December 2023 for developing novel therapies targeting high-risk AML patients reflects the strong commitment to innovation in the field. This investment is crucial for discovering new treatment modalities and improving existing ones, thus driving market growth. Additionally, collaborations and partnerships among pharmaceutical companies, research institutions, and academic centers are pivotal in accelerating the development of new AML therapies, further stimulating market expansion.

Despite these advancements, the AML treatment market faces several restraints. One of the primary challenges is the high cost associated with new therapies. The development, approval, and commercialization of innovative treatments often come with substantial expenses, making them expensive for patients and healthcare systems. This financial burden can limit access to the latest treatments, especially in low- and middle-income countries, thereby hindering the overall market growth.

Another significant restraint is the adverse side effects associated with AML treatments. While chemotherapy remains a cornerstone of AML treatment, it can cause severe side effects such as fatigue, nausea, and increased risk of infections. These side effects can significantly impact the quality of life for patients and sometimes lead to treatment discontinuation. Even newer targeted therapies, despite their precision, can pose challenges to patient tolerance. For instance, the combination of venetoclax with other treatments, while promising, has shown side effects that necessitate careful management.

Furthermore, the stringent regulatory environment poses another challenge. The approval process for new drugs is rigorous, requiring extensive clinical trials to ensure safety and efficacy. While these regulations are essential for patient safety, they can delay the introduction of new therapies to the market. This prolonged approval process can be a barrier to the timely availability of innovative treatments, impacting the market's ability to respond quickly to emerging therapeutic needs.

Global Acute Myeloid Leukemia Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research segmented the global acute myeloid leukemia treatment market report based on disease, treatment, route of administration, end-use, and region.

  • Disease Outlook (Revenue, USD Million, 2018 - 2030)
  • Myeloblastic Leukemia
  • Myelomonocytic Leukemia
  • Promyelocytic Leukemia
  • Monocytic Leukemia
  • Other Diseases
  • Treatment Outlook (Revenue, USD Million, 2018 - 2030)
  • Chemotherapy

Anti-metabolites

Alkylating Agents

Anthracycline Drugs

Others

  • Targeted Therapy

FLT3 Inhibitors

Rydapt

Vanflyta

Xospata

IDH Inhibitors

Tibsovo

Rezlidhia

Idhifa

Mylotarg

BCL-2 Inhibitor

Venclexta

Hedgehog Pathway Inhibitor

Daurismo

  • Immunotherapy

Bispecific Antibodies

Antibody-drug Conjugates

Immune Checkpoint Inhibitors

Chimeric Antigen Receptor (CAR) T-cell Therapy

  • Other Treatments
  • Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
  • Parenteral
  • Oral
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospital and Clinics
  • Specialty Centers
  • Homecare Settings
  • Ambulatory Care Centers
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

Germany

U.K.

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa (MEA)

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Treatment
    • 1.2.3. Route of Administration
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Treatment outlook
    • 2.2.3. Route of Administration outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Acute Myeloid Leukemia Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of acute myeloid leukemia
      • 3.2.1.2. Advancements in diagnostic techniques
      • 3.2.1.3. Growing investments in R&D techniques
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Limited treatment options
  • 3.3. Acute Myeloid Leukemia Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Acute Myeloid Leukemia Treatment Market: Disease Estimates & Trend Analysis

  • 4.1. Global Acute Myeloid Leukemia Treatment Market: Disease Dashboard
  • 4.2. Global Acute Myeloid Leukemia Treatment Market: Disease Movement Analysis
  • 4.3. Global Acute Myeloid Leukemia Treatment Market by Disease, Revenue
  • 4.4. Myeloblastic Leukemia
    • 4.4.1. Myeloblastic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Myelomonocytic Leukemia
    • 4.5.1. Myelomonocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Promyelocytic Leukemia
    • 4.6.1. Promyelocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Monocytic Leukemia
    • 4.7.1. Monocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Other Diseases
    • 4.8.1. Other diseases market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Acute Myeloid Leukemia Treatment Market: Treatment Estimates & Trend Analysis

  • 5.1. Global Acute Myeloid Leukemia Treatment Market: Treatment Dashboard
  • 5.2. Global Acute Myeloid Leukemia Treatment Market: Treatment Movement Analysis
  • 5.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, By Treatment, Revenue (USD Million)
  • 5.4. Chemotherapy
    • 5.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Anti-metabolites
      • 5.4.2.1. Anti-metabolites market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Alkylating agents
      • 5.4.3.1. Alkylating agents market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Anthracycline drugs
      • 5.4.4.1. Anthracycline drugs market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. FLT3 inhibitors
      • 5.5.2.1. FLT3 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

5.5.2.1.1. Rydapt

5.5.2.1.1.1. Rydapt market estimates and forecasts 2018 to 2030 (USD Million)

5.5.2.1.2. Vanflyta

5.5.2.1.2.1. Vanflyta market estimates and forecasts 2018 to 2030 (USD Million)

5.5.2.1.3. Xospata

5.5.2.1.3.1. Xospata market estimates and forecasts 2018 to 2030 (USD Million)

    • 5.5.3. IDH inhibitors
      • 5.5.3.1. IDH inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

5.5.3.1.1. Tibsovo

5.5.3.1.1.1. Tibsovo market estimates and forecasts 2018 to 2030 (USD Million)

5.5.3.1.2. Rezlidhia

5.5.3.1.2.1. Rezlidhia market estimates and forecasts 2018 to 2030 (USD Million)

5.5.3.1.3. Idhifa

5.5.3.1.3.1. Idhifa market estimates and forecasts 2018 to 2030 (USD Million)

    • 5.5.4. Mylotarg
      • 5.5.4.1. Mylotarg market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.5. BCL-2 inhibitor
      • 5.5.5.1. BCL-2 inhibitor market estimates and forecasts 2018 to 2030 (USD Million)

5.5.5.1.1. Venclexta

5.5.5.1.1.1. Venclexta market estimates and forecasts 2018 to 2030 (USD Million)

    • 5.5.6. Hedgehog pathway inhibitor
      • 5.5.6.1. Hedgehog pathway inhibitor market estimates and forecasts 2018 to 2030 (USD Million)

5.5.6.1.1. Daurismo

5.5.6.1.1.1. Daurismo market estimates and forecasts 2018 to 2030 (USD Million)

  • 5.6. Immunotherapy
    • 5.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.6.1.1. Bispecific antibodies

5.6.1.1.1. Bispecific antibodies market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.6.1.2. Antibody-drug conjugates
      • 5.6.1.3. Antibody-drug conjugates market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.6.1.4. Immune checkpoint inhibitors

5.6.1.4.1. Immune checkpoint inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.6.1.5. Chimeric antigen receptor (CAR) T-cell therapy

5.6.1.5.1. Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecasts 2018 to 2030 (USD Million)

  • 5.7. Other Treatments
    • 5.7.1. Other treatments market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Acute Myeloid Leukemia Treatment Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Dashboard
  • 6.2. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Movement Analysis
  • 6.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
  • 6.4. Parenteral
    • 6.4.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Acute Myeloid Leukemia Treatment Market: End Use Estimates & Trend Analysis

  • 7.1. Global Acute Myeloid Leukemia Treatment Market: End Use Dashboard
  • 7.2. Global Acute Myeloid Leukemia Treatment Market: End Use Movement Analysis
  • 7.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts by End Use, Revenue (USD Million)
  • 7.4. Hospital and Clinics
    • 7.4.1. Hospital and clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Specialty Centers
    • 7.5.1. Specialty Centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Homecare Setting
    • 7.6.1. Homecare setting market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Acute Myeloid Leukemia Treatment Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Vendor Landscape
    • 9.2.1. List of key distributors and channel partners
    • 9.2.2. Key customers
    • 9.2.3. Key company market share analysis, 2023
    • 9.2.4. Astellas Pharma Inc.
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Product benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. Bristol Myers Squibb Company
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Product benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. Celgene Corporation
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Product benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. Daiichi Sankyo Company, Limited
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Product benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Jazz Pharmaceuticals, plc
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Product benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Novartis AG
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Product benchmarking
      • 9.2.9.4. Strategic initiatives
    • 9.2.10. Otsuka Pharmaceuticals Co., Ltd.
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Product benchmarking
      • 9.2.10.4. Strategic initiatives
    • 9.2.11. Pfizer, Inc.
      • 9.2.11.1. Company overview
      • 9.2.11.2. Financial performance
      • 9.2.11.3. Product benchmarking
      • 9.2.11.4. Strategic initiatives
    • 9.2.12. Rigel Pharmaceuticals, Inc.
      • 9.2.12.1. Company overview
      • 9.2.12.2. Financial performance
      • 9.2.12.3. Product benchmarking
      • 9.2.12.4. Strategic initiatives
    • 9.2.13. Merck & Co., Inc.
      • 9.2.13.1. Company overview
      • 9.2.13.2. Financial performance
      • 9.2.13.3. Product benchmarking
      • 9.2.13.4. Strategic initiatives
    • 9.2.14. Sanofi
      • 9.2.14.1. Company overview
      • 9.2.14.2. Financial performance
      • 9.2.14.3. Product
      • 9.2.14.4. Benchmarking
      • 9.2.14.5. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 4 North America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 North America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 North America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 7 U.S. acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 8 U.S. acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 9 U.S. acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 U.S. acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 12 Canada acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Canada acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 Canada acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 16 Mexico acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Mexico acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 21 Europe acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 22 Europe acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Europe acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Germany acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 25 Germany acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Germany acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Germany acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 29 UK acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 30 UK acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 UK acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 33 France acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 34 France acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 France acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 37 Italy acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Italy acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Italy acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 41 Spain acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 Spain acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Spain acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Denmark acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 45 Denmark acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 Denmark acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Denmark Acute Myeloid Leukemia Treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Sweden acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 49 Sweden acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 50 Sweden acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Sweden acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Norway acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 53 Norway acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 Norway acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 Norway acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 61 China acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 62 China acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 63 China acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 China acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 66 Japan acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 67 Japan acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 Japan acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 70 India acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 71 India acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 India acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 73 South Korea acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 74 South Korea acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 75 South Korea acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 South Korea acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Australia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 78 Australia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 79 Australia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 Australia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Thailand acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 82 Thailand acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 83 Thailand acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 84 Thailand acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 86 Latin America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 87 Latin America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 88 Latin America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Latin America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 90 Brazil acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 91 Brazil acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 92 Brazil acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 93 Brazil acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 94 Argentina acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 95 Argentina acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 96 Argentina acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 97 Argentina acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 98 MEA acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 99 MEA acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 100 MEA acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 101 MEA acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 102 MEA acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 103 South Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 104 South Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 105 South Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 106 South Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 111 UAE acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 112 UAE acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 113 UAE acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 114 UAE acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 116 Kuwait acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 117 Kuwait acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 118 Kuwait acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Acute myeloid leukemia treatment market: market outlook
  • Fig. 14 Acute myeloid leukemia treatment competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Acute myeloid leukemia treatment market driver impact
  • Fig. 18 Acute myeloid leukemia treatment market restraint impact
  • Fig. 19 Acute myeloid leukemia treatment market: disease movement analysis
  • Fig. 20 Acute myeloid leukemia treatment market: disease outlook and key takeaways
  • Fig. 21 Myeloblastic leukemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Myelomonocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Promyelocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Postpartum post-traumatic stress disorder (PTSD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Monocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Other diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Acute myeloid leukemia treatment market: Treatment movement analysis
  • Fig. 28 Acute myeloid leukemia treatment market: Treatment outlook and key takeaways
  • Fig. 29 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Anti-metabolites market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Alkylating agents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Anthracycline drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 FLT3 inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Rydapt market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Vanflyta market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Xospata market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 IDH inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Tibsovo market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Rezlidhia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Idhifa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Mylotarg market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 BCL-2 inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Venclexta market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Hedgehog pathway inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Daurismo market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Bispecific antibodies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Antibody-drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Immune checkpoint inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Other treatments market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Acute myeloid leukemia treatment market: Route of administration movement analysis
  • Fig. 55 Acute myeloid leukemia treatment market: Route of administration outlook and key takeaways
  • Fig. 56 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Acute myeloid leukemia treatment market: End Use movement analysis
  • Fig. 59 Acute myeloid leukemia treatment market: End Use outlook and key takeaways
  • Fig. 60 Hospital and clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Specialty centers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Homecare setting market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Ambulatory care centers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Global acute myeloid leukemia treatment market: Regional movement analysis
  • Fig. 65 Global acute myeloid leukemia treatment market: Regional outlook and key takeaways
  • Fig. 66 Global acute myeloid leukemia treatment market share and leading players
  • Fig. 67 North America, by country
  • Fig. 68 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 U.S. key country dynamics
  • Fig. 70 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Canada key country dynamics
  • Fig. 72 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Mexico key country dynamics
  • Fig. 74 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 UK key country dynamics
  • Fig. 77 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Germany key country dynamics
  • Fig. 79 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 France key country dynamics
  • Fig. 81 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Italy key country dynamics
  • Fig. 83 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Spain key country dynamics
  • Fig. 85 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Denmark key country dynamics
  • Fig. 87 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Sweden key country dynamics
  • Fig. 89 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Norway key country dynamics
  • Fig. 91 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 China key country dynamics
  • Fig. 94 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Japan key country dynamics
  • Fig. 96 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 India key country dynamics
  • Fig. 98 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Thailand key country dynamics
  • Fig. 100 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 South Korea key country dynamics
  • Fig. 102 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Australia key country dynamics
  • Fig. 104 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Brazil key country dynamics
  • Fig. 107 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Argentina key country dynamics
  • Fig. 109 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 South Africa key country dynamics
  • Fig. 112 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Saudi Arabia key country dynamics
  • Fig. 114 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 UAE key country dynamics
  • Fig. 116 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Kuwait key country dynamics
  • Fig. 118 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Market share of key market players- acute myeloid leukemia treatment market